Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
The FDA is reviewing a petition to add pregnancy risk warnings to antidepressants, sparking concerns over conflict of interest and weak evidence.
The FDA is reviewing a petition to add a boxed warning to antidepressants like SSRIs over potential pregnancy risks, including miscarriage and fetal brain abnormalities, a move led by maternal-fetal medicine specialist Dr. Adam Urato.
Dr. Tracy Beth Hoeg, the FDA’s top drug regulator, is advancing the petition while reportedly working to hire Urato, raising conflict-of-interest concerns.
Critics say the evidence—based largely on animal studies and small human trials—is weak and could discourage pregnant women from taking necessary medication, risking harm from untreated depression.
Hoeg, who has no prior government experience and has questioned public health measures, has been accused of presenting Urato’s work as her own.
The FDA must respond in writing to all citizen petitions, and the situation has drawn scrutiny over impartiality in drug safety decisions.
La FDA está revisando una petición para agregar advertencias de riesgo de embarazo a los antidepresivos, provocando preocupaciones sobre el conflicto de intereses y la evidencia débil.